Moderna's Ups and Downs: Here's What You Need to Know Before Investing.

Core Insights - Moderna's stock has experienced volatility due to the decline in demand for its coronavirus vaccine and the cessation of approximately $500 million in U.S. funding for mRNA vaccine development [1][2] Group 1: Stock Performance - Moderna's stock initially surged during the pandemic but has since declined due to disappointing vaccine sales [3] - In January, Moderna's stock saw a 50% increase driven by optimism regarding a potential turnaround [3] Group 2: Company Developments - Moderna is at a pivotal transition, focusing on building a seasonal vaccine franchise and expanding its pipeline into oncology and rare diseases [4] - The company currently markets two coronavirus vaccines and an RSV vaccine, with plans to introduce a flu vaccine [5] Group 3: Regulatory and Market Outlook - The FDA initially declined to review Moderna's flu vaccine application but later agreed to review it after Moderna proposed a revised regulatory approach [5] - Moderna aims for seasonal vaccine sales growth to achieve cash breakeven by 2028 and projects up to 10% revenue growth for the current year [6]